Daxor Corporation

11.55+0.3000+2.67%Vol 14.10K1Y Perf -17.77%
Apr 9th, 2021 15:57 DELAYED
BID5.00 ASK17.00
Open11.25 Previous Close11.25
Pre-Market- After-Market-
 - -  - -%
Target Price
21.50 
Analyst Rating
Moderate Buy 2.00
Potential %
86.15 
Finscreener Ranking
★★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+ —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap44.92M 
Earnings Rating
Buy
Price Range Ratio 52W %
4.06 
Earnings Date
28th Mar 2012

Today's Price Range

11.2511.75

52W Range

11.0224.08

5 Year PE Ratio Range

-98.1027.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.15%
1 Month
-4.70%
3 Months
-5.56%
6 Months
-23.91%
1 Year
-17.77%
3 Years
35.72%
5 Years
43.30%
10 Years
17.94%

TickerPriceChg.Chg.%
DXR11.550.30002.67
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q04 2011--0.35-
Q03 2011--0.99-
Q02 2011--0.04-
Q01 2011--0.31-
Q04 2010-0.53-
Q03 2010-0.62-
Q02 2010-0.04-
Q01 2010--0.02-
Earnings Per EndEstimateRevision %Trend
12/2007 QR---
3/2008 QR---
12/2020 FY0.150.00-
12/2021 FY0.400.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume14.10K
Shares Outstanding3.89M
Trades Count91
Dollar Volume17.56K
Avg. Volume9.86K
Avg. Weekly Volume16.91K
Avg. Monthly Volume10.28K
Avg. Quarterly Volume10.52K

Daxor Corporation (AMEX: DXR) stock closed at 11.55 per share at the end of the most recent trading day (a 2.67% change compared to the prior day closing price) with a volume of 14.10K shares and market capitalization of 44.92M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 750 people. Daxor Corporation CEO is Michael Feldschuh.

The one-year performance of Daxor Corporation stock is -17.77%, while year-to-date (YTD) performance is -7.6%. DXR stock has a five-year performance of 43.3%. Its 52-week range is between 11.02 and 24.08, which gives DXR stock a 52-week price range ratio of 4.06%

Daxor Corporation currently has a PE ratio of -43.20, a price-to-book (PB) ratio of 3.11, a price-to-sale (PS) ratio of -48.39, a price to cashflow ratio of 26.90, a PEG ratio of 2.32, a ROA of -10.65%, a ROC of -% and a ROE of -11.53%. The company’s profit margin is 63.08%, its EBITDA margin is -%, and its revenue ttm is $-987 897.00 , which makes it $-0.24 revenue per share.

Of the last four earnings reports from Daxor Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Daxor Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for Daxor Corporation is Moderate Buy (2), with a target price of $21.5, which is +86.15% compared to the current price. The earnings rating for Daxor Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Daxor Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Daxor Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 33.16, ATR14 : 0.88, CCI20 : -32.90, Chaikin Money Flow : -0.26, MACD : -0.43, Money Flow Index : 37.84, ROC : 1.22, RSI : 51.56, STOCH (14,3) : 55.21, STOCH RSI : 1.00, UO : 43.70, Williams %R : -44.79), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Daxor Corporation in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (33.33 %)
1 (33.33 %)
Moderate Buy
0 (0.00 %)
1 (33.33 %)
1 (33.33 %)
Hold
1 (50.00 %)
1 (33.33 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

Daxor Corporation

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

CEO: Michael Feldschuh

Telephone: +1 212 330-8500

Address: 350 Fifth Avenue, New York 10118, NY, US

Number of employees: 750

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

55%45%

Bearish Bullish

55%45%

News

Stocktwits